Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2 diabetes

Hsin-Hung Chen 1 2, Ching-Chu Chen 3 4, Chun-Wei Ho 1, Ming-Chia Hsieh 1 5 6, Sheng-Pang Hsu 3, Cheng-Li Lin 7 8, Chia-Hung Kao 9 10 11 12

Main idea: For public health issue with type2 diabetes and infection, DPP4i use decreased Klebsiella pneumoniae pneumonia. Male gender, patients with co-morbidities, patients with higher DSCI score and higher DDD of DPP4i were observed to decrease Klebsiella pneumoniae pneumonia infection in our analysis.

Abstract

Objectives: To investigate the effect of dipeptidyl peptidase-4 inhibitor (DPP4i) for Klebsiella pneumoniae (KP) pneumonia in patients with diabetes.

Patients and methods: Patients newly diagnosed with type 2 diabetes from 2009 to 2012 were recruited for this population-based and observational study. Diabetes complications severity index (DCSI) score and defined daily dose (DDD) were used for analysis. The multivariable Cox proportional hazards models were used to estimate the risk of KP pneumonia by DPP4i use, with adjustments for propensity score. The Kaplan-Meier method with the log-rank test was used to estimate the risk of KP pneumonia for DPP4i users.

Results: DDP4i users had a significantly lower risk of developing KP pneumonia compared with nonusers. The incidence rate of KP pneumonia was 1.51 per 1000 person-years in users and 2.25 per 1000 people-years for comparison.

Source NIH